Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.

Grade Last Price % Change Price Change
grade B 3.08 3.36% 0.10
CPRX closed up 3.36 percent on Monday, March 18, 2019, on 1.39 times normal volume.

Earnings due: Mar 19

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CPRX trend table...

Date Alert Name Type % Chg
Mar 18 MACD Bullish Signal Line Cross Bullish 0.00%
Mar 18 Bollinger Band Squeeze Range Contraction 0.00%
Mar 18 BB Squeeze + Upper Band Touch Range Contraction 0.00%
Mar 18 Upper Bollinger Band Touch Strength 0.00%
Mar 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.36%
Mar 15 Bollinger Band Squeeze Range Contraction 3.36%
Mar 15 Overbought Stochastic Strength 3.36%
Mar 14 MACD Bearish Signal Line Cross Bearish 3.01%
Mar 14 Bollinger Band Squeeze Range Contraction 3.01%
Mar 14 Overbought Stochastic Strength 3.01%

Older signals for CPRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Health Pharmaceutical Pharmaceutical Industry California Medication Disorders Health Sciences Virotherapy Epilepsy Pharmaceutical Sciences Biomarin Pharmaceutical Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato Tourette Syndrome Treatment Of Epilepsy
Is CPRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.05
52 Week Low 1.85
Average Volume 969,762
200-Day Moving Average 2.9503
50-Day Moving Average 2.6714
20-Day Moving Average 2.922
10-Day Moving Average 2.951
Average True Range 0.1369
ADX 15.05
+DI 26.2847
-DI 17.3282
Chandelier Exit (Long, 3 ATRs ) 2.7693
Chandelier Exit (Short, 3 ATRs ) 2.9907
Upper Bollinger Band 3.1231
Lower Bollinger Band 2.7209
Percent B (%b) 0.89
BandWidth 13.764545
MACD Line 0.1056
MACD Signal Line 0.105
MACD Histogram 0.0007
Fundamentals Value
Market Cap 260.42 Million
Num Shares 84.6 Million
EPS -0.20
Price-to-Earnings (P/E) Ratio -15.40
Price-to-Sales 0.00
Price-to-Book 6.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.37
Resistance 3 (R3) 3.37 3.27 3.32
Resistance 2 (R2) 3.27 3.20 3.27 3.30
Resistance 1 (R1) 3.18 3.16 3.23 3.18 3.29
Pivot Point 3.08 3.08 3.11 3.08 3.08
Support 1 (S1) 2.99 3.01 3.04 2.99 2.87
Support 2 (S2) 2.89 2.97 2.89 2.86
Support 3 (S3) 2.80 2.89 2.84
Support 4 (S4) 2.80